PE20110598A1 - Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 - Google Patents

Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38

Info

Publication number
PE20110598A1
PE20110598A1 PE2011000797A PE2011000797A PE20110598A1 PE 20110598 A1 PE20110598 A1 PE 20110598A1 PE 2011000797 A PE2011000797 A PE 2011000797A PE 2011000797 A PE2011000797 A PE 2011000797A PE 20110598 A1 PE20110598 A1 PE 20110598A1
Authority
PE
Peru
Prior art keywords
alkyl
tolil
ureide
methyl
optionally substituted
Prior art date
Application number
PE2011000797A
Other languages
English (en)
Inventor
Kazuhiro Ito
Catherine Elisabeth Charron
David Michel Adrien Taddei
Stuart Thomas Onions
Peter Strong
Simon Christopher Hirst
Jonathan Gareth Williams
John King-Underwood
Peter John Murray
William Garth Rapeport
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0818033.3A external-priority patent/GB0818033D0/en
Priority claimed from GB0822609A external-priority patent/GB0822609D0/en
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of PE20110598A1 publication Critical patent/PE20110598A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE (P-TOLIL-1H-PIRAZOL-5-IL)UREIDO DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON OH; R2 ES H O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON OH; R3 ES H, ALQUILO(C1-C6) O ALQUILO(C0-C3)-CICLOALQUILO(C3-C6); Ar ES NAFTILO O FENILO OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C6), ALCOXI(C1-C6), NH2, ENTRE OTROS; L ES ALQUILENO(C1-C8) OPCIONALMENTE SUSTITUIDO CON HALOGENO; X ES HETEROARILO DE 5 O 6 MIEMBROS; Q ES ALQUILO(C1-C10) O ALQUILO(C0-C8)-HETEROCICLILO. SON COMPUESTOS PREFERIDOS: N-(4-((4-(3-(3-TERC-BUTIL-1-P-TOLIL-1H-PIRAZOL-5-IL)UREIDO)NAFTALEN-1-ILOXI)METIL)PIRIDIN-2-IL)-2-METOXIACETAMIDA; METIL 4-((4-(3-(3-TERC-BUTIL-1-P-TOLIL-1H-PIRAZOL-5-IL)UREIDO)NAFTALEN-1-ILOXI)METIL)PIRIDIN-2-ILUREA; N-(4-((4-(3-(3-TERC-BUTIL-1-P-TOLIL-1H-PIRAZOL-5-IL)UREIDO)NAFTALEN-1-ILOXI)METIL)PIRIDIN-2-IL)TETRAHIDRO-2H-PIRAN-4-CARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS ENZIMAS DE PROTEINA CINASA ACTIVADAS POR MITOGENO p38 (MAP CINASA p38) SIENDO UTILES EN EL TRATAMIENTO DE ASMA, FIBROSIS QUISTICA, RINITIS ALERGICA, SINUSITIS
PE2011000797A 2008-10-02 2009-10-02 Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 PE20110598A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0818033.3A GB0818033D0 (en) 2008-10-02 2008-10-02 Novel compound
GB0822609A GB0822609D0 (en) 2008-12-11 2008-12-11 Novel compounds

Publications (1)

Publication Number Publication Date
PE20110598A1 true PE20110598A1 (es) 2011-08-31

Family

ID=42027990

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000797A PE20110598A1 (es) 2008-10-02 2009-10-02 Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38

Country Status (23)

Country Link
US (3) US8293748B2 (es)
EP (1) EP2350049B1 (es)
JP (1) JP2012504591A (es)
KR (1) KR20110070887A (es)
CN (1) CN102256964A (es)
AU (1) AU2009299555B2 (es)
BR (1) BRPI0920707A2 (es)
CA (1) CA2738828A1 (es)
CL (1) CL2011000737A1 (es)
CO (1) CO6351786A2 (es)
CR (1) CR20110477A (es)
EA (1) EA020641B1 (es)
EC (1) ECSP11010949A (es)
ES (1) ES2461496T3 (es)
HK (1) HK1160129A1 (es)
HN (1) HN2011000876A (es)
MX (1) MX2011003553A (es)
MY (1) MY159230A (es)
NI (1) NI201100063A (es)
NZ (1) NZ591427A (es)
PE (1) PE20110598A1 (es)
WO (1) WO2010038086A2 (es)
ZA (1) ZA201103180B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2229391B1 (en) 2007-12-19 2014-08-06 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0818033D0 (en) * 2008-10-02 2008-11-05 Respivert Ltd Novel compound
MX2011003553A (es) * 2008-10-02 2011-05-25 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
EP2370428B1 (en) 2008-12-11 2016-08-10 Respivert Limited P38 map kinase inhibitors
EP4403231A2 (en) 2009-02-26 2024-07-24 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921730D0 (en) * 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
JP5787977B2 (ja) * 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤
JP5787976B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
US8933228B2 (en) 2010-06-17 2015-01-13 Respivert, Ltd. Respiratory formulations and compounds for use therein
MY167798A (en) 2011-10-03 2018-09-26 Respivert Ltd 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors
EP2578582A1 (en) * 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
WO2014033449A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
WO2014033447A2 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
EP2890460B1 (en) 2012-08-29 2017-02-22 Respivert Limited Kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
CN105408315B (zh) 2013-04-02 2018-09-14 瑞斯比维特有限公司 激酶抑制剂
WO2014162121A1 (en) 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
AU2014280123B2 (en) 2013-06-14 2019-11-14 Akamis Bio Limited A dosing regime and formulations for type B adenoviruses
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
US9890185B2 (en) 2013-12-20 2018-02-13 Respivert Limited Urea derivatives useful as kinase inhibitors
CN113264921B (zh) 2014-02-14 2024-09-13 瑞斯比维特有限公司 作为激酶抑制剂的吡唑基-脲
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
CA3015978A1 (en) 2016-04-06 2017-10-12 Topivert Pharma Limited Kinase inhibitors
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018160138A1 (en) 2017-03-02 2018-09-07 Aslan Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
US11981723B2 (en) 2017-09-05 2024-05-14 GLAdiator Biosciences, Inc. Method of targeting exosomes
WO2019083455A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS
WO2019083456A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS
WO2019083458A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA
WO2019083457A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY
AU2019323714A1 (en) 2018-08-24 2021-03-25 Jaguahr Therapeutics Pte Ltd Tetrahydropyridopyrimidine derivatives as AhR modulators
SG11202104073XA (en) 2018-10-09 2021-05-28 Aslan Pharmaceuticals Pte Ltd Malonate salt of varlitinib
KR20210000491U (ko) 2019-08-21 2021-03-04 이윤병 포장밴드 절단구
AU2021226411A1 (en) 2020-02-26 2022-09-22 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of AhR signalling
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080763A (en) 1997-11-03 2000-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds and their use as anti-inflammatory agents
DE1043995T1 (de) * 1997-12-22 2001-06-07 Bayer Corp., Pittsburgh INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
AU2198999A (en) * 1997-12-22 1999-07-12 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
WO1999032111A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
EP1056725B1 (en) 1997-12-22 2006-06-07 Bayer Pharmaceuticals Corp. Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
CA2319493A1 (en) 1998-03-18 1999-09-23 Regine Bohacek Heterocyclic signal transduction inhibitors, compositions containing them
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
WO2002066442A1 (en) 2001-02-15 2002-08-29 Boehringer Ingelheim Pharmaceuticals, Inc. Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
MXPA03010487A (es) 2001-05-16 2004-03-09 Boehringer Ingelheim Pharma Derivados de diarilurea utiles como agentes antiinflamatorios.
EP1408950B1 (en) 2001-07-11 2007-04-25 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
JP4629978B2 (ja) * 2002-02-25 2011-02-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物
CA2479520A1 (en) 2002-04-05 2003-10-16 Birgit Jung P38 kinase inhibitors for treating mucus hypersecretion_
EP1545523A1 (en) * 2002-07-03 2005-06-29 Astex Technology Limited 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
WO2004021988A2 (en) 2002-09-05 2004-03-18 Scios Inc. Treatment of pain by inhibition of p38 map kinase
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
ES2357288T3 (es) 2003-02-28 2011-04-25 Bayer Healthcare Llc Derivados de 2-oxo-1,3,5-perhidrotriazapina útiles en el tratamiento de angiogénesis hiperproliferativa y trastornos inflamatorios.
US7521447B2 (en) 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
GB0308511D0 (en) 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
WO2004101529A1 (ja) 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
AU2004266719A1 (en) 2003-08-22 2005-03-03 Boehringer Ingelheim France S.A.S. Methods of treating COPD and pulmonary hypertension
AU2004291147A1 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
WO2005115397A2 (en) 2004-04-29 2005-12-08 Pharmix Corporation Compositions and treatments for modulating kinase and/or hmg-coa reductase
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
KR20070032648A (ko) 2004-05-12 2007-03-22 브리스톨-마이어스 스큅 컴퍼니 혈전 상태의 치료에 유용한 ｐ２ｙ１ 수용체의 우레아길항제
PT1761520E (pt) 2004-06-23 2008-09-15 Lilly Co Eli Inibidores de quinase
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
JP2008523072A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
WO2006068591A1 (en) 2004-12-20 2006-06-29 Astrazeneca Ab Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors
AU2005325676A1 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
AU2005321946B2 (en) 2004-12-23 2012-08-16 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
GB0500435D0 (en) * 2005-01-10 2005-02-16 Novartis Ag Organic compounds
DE102005015253A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Pyrazolderivate
EP1885181A2 (en) 2005-05-23 2008-02-13 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
ES2444690T3 (es) 2005-06-20 2014-02-26 Janssen R&D Ireland Bencimidazoles sustituidos con heterociclilaminoalquilo.
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
WO2007038425A2 (en) 2005-09-27 2007-04-05 Regents Of The University Of Minnesota Anti-viral compouinds
WO2007059202A2 (en) * 2005-11-15 2007-05-24 Bayer Healthcare Ag Pyrazolyl urea derivatives useful in the treatment of cancer
WO2007064872A2 (en) * 2005-12-01 2007-06-07 Bayer Healthcare Llc Urea compounds useful in the treatment of cancer
WO2007089512A1 (en) 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators
DE602007008524D1 (de) 2006-01-30 2010-09-30 Irm Llc Spiroimidazol-derivate als ppar-modulatoren
AR062207A1 (es) 2006-08-04 2008-10-22 Takeda Pharmaceutical Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
WO2008114119A2 (en) 2007-03-20 2008-09-25 Cadila Pharmaceuticals Limited P38 inhibitors
JP5475776B2 (ja) * 2008-07-31 2014-04-16 ヒューレット−パッカード デベロップメント カンパニー エル．ピー． 多層型再構成可能スイッチ
MX2011003553A (es) * 2008-10-02 2011-05-25 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
EP2370428B1 (en) 2008-12-11 2016-08-10 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds

Also Published As

Publication number Publication date
EP2350049B1 (en) 2014-02-26
NZ591427A (en) 2012-12-21
WO2010038086A3 (en) 2010-06-24
US8293748B2 (en) 2012-10-23
EA020641B1 (ru) 2014-12-30
MX2011003553A (es) 2011-05-25
AU2009299555B2 (en) 2014-01-16
ES2461496T3 (es) 2014-05-20
CA2738828A1 (en) 2010-04-08
AU2009299555A1 (en) 2010-04-08
NI201100063A (es) 2011-10-21
BRPI0920707A2 (pt) 2015-12-29
US8975285B2 (en) 2015-03-10
US20140114064A1 (en) 2014-04-24
JP2012504591A (ja) 2012-02-23
ZA201103180B (en) 2012-10-31
CO6351786A2 (es) 2011-12-20
WO2010038086A8 (en) 2011-04-28
CN102256964A (zh) 2011-11-23
US8618140B2 (en) 2013-12-31
CL2011000737A1 (es) 2011-10-14
HK1160129A1 (en) 2012-08-10
HN2011000876A (es) 2014-01-20
WO2010038086A2 (en) 2010-04-08
CR20110477A (es) 2012-06-04
MY159230A (en) 2016-12-30
ECSP11010949A (es) 2011-06-30
EP2350049A2 (en) 2011-08-03
EA201170521A1 (ru) 2011-12-30
KR20110070887A (ko) 2011-06-24
US20130012512A1 (en) 2013-01-10
US20110212962A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20141375A1 (es) Activadores de glucoquinasa
PE20110810A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20081659A1 (es) Agonistas de gpcr
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20110329A1 (es) Agonistas del receptor acoplado a la proteina g piperidinilo
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20140502A1 (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
PE20081532A1 (es) Compuestos novedosos
PE20120632A1 (es) Inhibidores de bace
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
PE20090244A1 (es) Inhibidores de la proteina activadora de la 5-lipoxigenasa (flap)
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20081195A1 (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20090815A1 (es) Compuesto de amida
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20080858A1 (es) Compuestos de n-aril pirazol y composiciones que los contienen

Legal Events

Date Code Title Description
FC Refusal